40 min listen
B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal
FromKeeping Current
ratings:
Length:
47 minutes
Released:
Nov 16, 2021
Format:
Podcast episode
Description
Join our expert faculty as they discuss next-generation BTK inhibitors, with a focus on specificity, efficacy, and tolerability. Credit available for this activity expires: 11/16/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/962783?src=mkm_podcast_addon_962783
Released:
Nov 16, 2021
Format:
Podcast episode
Titles in the series (100)
Implementing Multiple Myeloma Clinical Trial Data in Real-World Practice: Experts in the field discuss how to implement the newest data in multiple myeloma into the real-world clinical practice. --- Full URLs: Earn Credit / Learning Objectives & Disclosures:... by Keeping Current